Alzamend Neuro, Inc. (ALZN) Financial Statements (2024 and earlier)

Company Profile

Business Address 3500 LENOX RD. NE
ATLANTA, GA 30326
State of Incorp. DE
Fiscal Year End April 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

1/31/2024
MRQ
4/30/2023
4/30/2022
4/30/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5,140,85914,063,8111,929,270
Cash and cash equivalents5,140,85914,063,8111,929,270
Prepaid expense247,334163,056850
Deferred costs   352,502
Other undisclosed current assets447,589186,667629,968
Total current assets:5,835,78214,413,5342,912,590
Noncurrent Assets
Property, plant and equipment79,843102,909 
Total noncurrent assets:79,843102,909 
TOTAL ASSETS:5,915,62514,516,4432,912,590
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,870,1221,162,850503,591
Accounts payable2,870,1221,162,850503,591
Due to related parties 2,08260,749
Other undisclosed current liabilities   335,303
Total current liabilities:2,870,1221,164,932899,643
Noncurrent Liabilities
Liabilities, other than long-term debt   
Accounts payable and accrued liabilities   
Total noncurrent liabilities:   
Total liabilities:2,870,1221,164,932899,643
Equity
Equity, attributable to parent, including:3,045,50313,351,5112,012,947
Preferred stock   75
Common stock9,6949,5486,743
Additional paid in capital61,991,76657,419,75333,721,860
Accumulated deficit(44,072,662)(29,194,495)(16,832,436)
Stockholders' equity note, subscriptions receivable   
Other undisclosed equity, attributable to parent (14,883,295)(14,883,295)(14,883,295)
Total equity:3,045,50313,351,5112,012,947
Other undisclosed liabilities and equity   
TOTAL LIABILITIES AND EQUITY:5,915,62514,516,4432,912,590

Income Statement (P&L) (USD)

1/31/2024
TTM
4/30/2023
4/30/2022
4/30/2021
Operating expenses(14,870,466)(12,319,535)(4,951,888)
Operating loss:(14,870,466)(12,319,535)(4,951,888)
Nonoperating expense(7,701)(42,524)(94,679)
Interest and debt expense(7,701)4,00062,418
Loss from continuing operations before equity method investments, income taxes:(14,885,868)(12,358,059)(4,984,149)
Other undisclosed income (loss) from continuing operations before income taxes7,701(4,000)(62,418)
Loss from continuing operations:(14,878,167)(12,362,059)(5,046,567)
Loss before gain (loss) on sale of properties:(12,362,059)(5,046,567)
Other undisclosed net income29,778,167  
Net income (loss):14,900,000(12,362,059)(5,046,567)
Other undisclosed net loss attributable to parent(29,778,167)  
Net loss available to common stockholders, diluted:(14,878,167)(12,362,059)(5,046,567)

Comprehensive Income (USD)

1/31/2024
TTM
4/30/2023
4/30/2022
4/30/2021
Net income (loss):14,900,000(12,362,059)(5,046,567)
Comprehensive income (loss), net of tax, attributable to parent:14,900,000(12,362,059)(5,046,567)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: